Type 2 diabetes

What's new in the 2019 update to the ADA guidelines on nutrition therapy for adults with diabetes or prediabetes? Diabetes Educator Amy Hess Fischl explains.

Research Dietitian Pam Dyson and General Practitioner Liz Morris discuss how improvements in nutrition science have impacted guidance around low-glycemic index diets and carbohydrate intake (2:43).

Egg diets? Alkaline diets? Raspberry ketones? Pam Dyson and Liz Morris discuss how to handle your patients' questions about these dietary approaches and more (5:13).

Research Dietitian Pam Dyson and General Practitioner Liz Morris discuss evidence-based dietary recommendations for the management of type 2 diabetes (11:40).

WATCH | Research Dietitian Pam Dyson and General Practitioner Liz Morris discuss the efficacy and safety of low-fat healthy eating, low-calorie, Mediterranean and meal replacement diets for the management of type 2 diabetes (4:29).

WATCH | Research dietitian Pam Dyson and General practitioner Liz Morris discuss the benefits and drawbacks of low-carb diets as well as the positive evidence for structured weight management in people with type 2 diabetes (4:52).

WATCH | Research Dietitian Pam Dyson and General Practitioner Liz Morris discuss the findings from the DiRECT trial, including the real-world implications for recommending a diet that can put type 2 diabetes into remission (2:18).

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity.

medwireNews talks to one of the pioneers of closed-loop insulin delivery, Roman Hovorka, about his algorithm, his research so far, and his plans for commercialization.

medwireNews rounds up the ongoing, reported, and published trials from the PIONEER oral semaglutide program.

How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.

The recent postmarketing data on Fournier gangrene in people taking sodium-glucose cotransporter 2 inhibitors has increased concerns about this very rare but potentially fatal side effect. medwireNews talks to primary care diabetes specialist Kevin Fernando about how the findings affect risk–benefit considerations.

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.

Nephrologist Katherine Tuttle and Primary Care Physician Jay Shubrook discuss referrals to nephrology for patients with comorbid diabetes and kidney disease (8:38).

What does the proliferation of diabetes self-management and monitoring technologies in pediatric care mean for the future of adult services? Katharine Barnard looks at the situation in England and Wales.

Escalating obesity prevalence and severity has led to type 2 diabetes being diagnosed in ever-younger people, including children. medwireNews rounds up the accumulating evidence suggesting a particularly severe diabetes course in these young people.

Editorial board member Jay Shubrook explains how the aggressive course of young-onset type 2 diabetes affects clinical decision-making for primary care providers.

Consultant nephrologist Andrew Frankel tells medwireNews about the rationale and key findings of the CREDENCE trial, and discusses the potential benefits of SGLT2 inhibitors beyond type 2 diabetes (9:45).

General practitioner Kevin Fernando talks to medwireNews about the importance of the CREDENCE trial from a primary care perspective (4:43).

Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial – demonstrating that canagliflozin is associated with a reduced risk for kidney failure and cardiovascular events in people with type 2 diabetes and chronic kidney disease – and discusses how these results will impact clinical practice (6:51).